Skip to Main Content

Advertisement

Skip Nav Destination

Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results

Blood (2021) 138 (Supplement 1): 3542.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement